Jun 14: The Competition Commission of India (CCI) approves the acquisition of the Corporate restructuring of GlaxoSmithKline Consumer Healthcare Holdings (No.2) Limited (“JVCO”) under Section 31(1) of the Competition Act, 2002.
The Proposed Combination involves the corporate restructuring of JVCO, including through acquisition by Haleon via demerger and the share exchange steps involving the shareholders of JVCO. Immediately following completion of the demerger and share exchange steps, the shareholding of Haleon will be held by a combination of GSK, GSK’s affiliates, and GSK’s shareholders (together representing 68% of Haleon’s voting rights) and (directly/indirectly) Pfizer (representing 32% of Haleon’s voting rights).
GSK, registered in the UK, is a pharmaceutical company active worldwide in the research, development, manufacturing, and marketing of prescription pharmaceuticals, vaccines, and consumer healthcare products. In the consumer healthcare segment, it is active in the research, development, manufacturing, and marketing of products that are typically available without a prescription (i.e., OTC), for various indications.
Pfizer is a research-based biopharmaceutical company and is engaged globally in the research, development, manufacturing, and marketing of innovative medicines.
Haleon is a newly incorporated entity that presently does not have any business activities.
JVCO was established in 2019, combining the respective legacy consumer healthcare business worldwide, including India, of GSK and Pfizer. JVCO (through its subsidiaries and affiliates) is engaged in the manufacture and distribution of consumer healthcare products.
Detailed order of the CCI will follow.
****
Disclaimer: We donot claim that the images used as part of the news published are always owned by us. From time to time, we use images sourced as part of news or any related images or representations. Kindly take a look at our image usage policy on how we select the image that are used as part of the news.
